Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway.

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

ReNeuron wants to renew damaged brain cells with stem cell therapy. Founded in 1997 by leading scientists at the London-based Institute of Psychiatry, the company is researching the feasibility of transplanting stem cells into patients with Parkinson's disease, Huntington's disease, type 1 diabetes, stroke, and other neurological disorders. ReNeuron also is studying the possible use of stem cells to treat brain tumors and in non-therapeutic areas with its ReNcell drug development platform. Investors include Merlin Ventures, a leading UK biotechnology investor.

Aastrom Biosciences, Inc. company was founded in 1989 and is headquartered in Ann Arbor, Michigan. Aastrom Biosciences, Inc. is a regenerative medicine company and focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on its Tissue Repair Cell (TRC) technology. The Company’s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations and are investigated for their ability to aid in the regeneration of tissues, such as cardiac, vascular and bone. TRC-based products have been used in over 350 patients, and its stages of development are Cardiac regeneration includes Cardiac Repair Cells (CRCs); Dilated cardiomyopathy (DCM) (severe heart failure); Vascular regeneration includes Vascular Repair Cells (VRCs); Critical limb ischemia (CLI); Bone regeneration includes Bone Repair Cells (BRCs); Osteonecrosis of the femoral head; Non-union fractures, and Maxillofacial.

Carma Laboratories, Inc. company was founded by Alfred Woelbing, who developed the formula for Carmex in 1937 as a treatment for his own cold sores. Carma Laboratories wants to make it easier for you to smile and sit. The family-owned-and-operated company is most famous for its retro yellow-lidded vials of Carmex lip balm. The company also makes Am-Ren, a zinc-oxide based diaper rash ointment, and LANEX hemorrhoid ointment to soothe cracked and painful tissues elsewhere. Once sold mostly in the Midwest and the ski areas of the Rockies, Carmex soothes lips in all 50 states, Canada, Australia, and Europe.

EMD Serono develops a potpourri of prescription pharmaceuticals used for the treatment of neurological, metabolic, and fertility disorders and diseases such as multiple sclerosis (MS), lupus, and HIV. The Massachusetts-based company conducts research and development programs in the US and markets products that include Gonal-f, Luveris, Ovidrel, Rebif, and Zorbtive in the US and Canada. The company has manufacturing and marketing agreements with other pharmaceutical firms, including Pfizer (MS) and CuraScript (fertility). EMD Serono is the North American operating subsidiary of Merck Serono S.A..

BioFocus DPI takes the guesswork out of your drug discovery. The UK-based company specializes in pre-clinical drug discovery services, assay development and screening, and compound management (including storage and delivery). The company's major clients include Pfizer, Procter & Gamble, and GlaxoSmithKline. BioFocus was founded by a group of Wellcome scientists in 1997, and about a decade later was acquired by Galapagos. It now operates as that company's services division. Formerly known as BioFocus, the firm added DPI to its name after Galapagos acquired the drug discovery business of Discovery Partners International and merged it with existing BioFocus operations.

Inovio Biomedical Corporation was founded in 1983 and is based in San Diego, California. Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio's proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio's clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.